歌礼制药(01672.HK)ASC30美国Ib期试验取得积极期中结果

阿斯达克财经
31 Mar

歌礼制药-B(01672.HK) 公布,其在美国开展的随机、双盲、安慰剂对照的ASC30单次皮下注射Ib期研究取得积极期中结果,该试验在肥胖症患者中进行,含小分子ASC30的三种超长效皮下注射制剂。小分子ASC30超长效皮下注射剂在肥胖症患者中显示出36天的半衰期,支持每月一次或更低频率给药。

据此前披露的数据,肥胖症患者接受小分子ASC30口服片剂治疗4周后,体重下降6.3%,小分子ASC30口服片剂有望成为同类最佳药物。(de/d)(港股报价延迟最少十五分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10